Phase I/II Study of ASP9521 in Castrate-Resistant Prostate Cancer (CRPC) Patients
Stopped It was decided to discontinue the development in consideration of the results of a P1 study
Conditions
- Castrate Resistant Prostate Cancer
Interventions
Sponsor
Astellas Pharma Inc